ID | Virological outcome after at least 6Â months of HAART | Genotype | Baseline resistance mutations (% prevalence) | Drug activity of initiated regimen (Based on drug resistance mutation surveillance list [31]) | Drug activity of initiated regimen (Based on impact of treatment efficacy Stanford HIVdb algorithm) | ||
---|---|---|---|---|---|---|---|
NRTIs | NNRTIs | TAMS | |||||
L001 | Suppressed | C | D67E (1.67) T69N (1.25) F77L (2.16) | P225H (1.35) F227L (2.36) | 1 | TDF and FTC resistance EFV resistance | TDF susceptible FTC susceptible EFV resistance |
L009 | Detectable viremia (<1000 RNA copies/ml) | C | D67E (1.29) T69N (1.03) F77L (1.15) L100I (1.15) KI03N (4.17) | F227L (1.49) | 1 | TDF and FTC resistance EFV resistance | TDF susceptible FTC susceptible EFV high level resistance |
L013 | Virological failure | C | D67E (1.73) T69N (1.21) F77L (1.13) | P225H (1.16) F227L (1.98) | 1 | TDF and FTC resistance EFV resistance | TDF susceptible FTC susceptible EFV low level resistance |
L031 | Virological failure | C | D67E (1.05) F77L (1.02) | F227L (1.78) | 1 | TDF and FTC susceptible EFV resistance | TDF susceptible FTC susceptible EFV resistance |
L054 | Virological failure | C | A62V (1.51) D67E (1.16) F77L (1.52) | F227L (1.26) | 1 | TDF resistance and FTC susceptible EFV resistance | TDF resistance FTC susceptible EFV resistance |
L064 | Virological failure | C | D67E (1.32) | F227L (1.43) | 1 | TDF and FTC susceptible EFV susceptible | TDF susceptible FTC susceptible EFV resistance |
L074 | Suppressed | CRF37_cpx | D67E (1.72) T69N (1.34) M184I (1.04) | P225H (1.12) F227L (1.86) | 1 | TDF and FTC resistance EFV resistance | TDF susceptible FTC resistance EFV resistance |
L075 | Suppressed | CRF37_cpx | D67E (1.83) T69N (1.58) L74V (1.23) F77L (1.01) M184I (1.44) | P225H (2.22) F227L (1.47) | 1 | TDF and FTC resistance EFV resistance | TDF susceptible FTC resistance EFV low level resistance |